ARGENX
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.
ARGENX
Industry:
Biotechnology Clinical Trials Therapeutics
Founded:
2008-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.argenx.com
Total Employee:
501+
Status:
Active
Contact:
833-274-9411.
Total Funding:
3.75 B USD
Technology used in webpage:
IPhone / Mobile Compatible Domain Not Resolving SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS Common Name Invalid ASP.NET IIS Sectigo SSL
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Apeiron Biologics
Apeiron Biologics is a biotech company that focuses on the discovery and development of novel cancer immunotherapies.
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Georgiamune
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Oxford BioMedica
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research.
Scout Bio
Scout Bi is a biotechnology company that provides veterinary, animal health, and gene therapy.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Current Advisors List
Board_member
2023-03-01
Current Employees Featured
Christophe Blanchetot Director Discovery @ argenx
Director Discovery
2016-01-01
Tom Hughes HEOR Launch Consultant @ argenx
HEOR Launch Consultant
2021-03-01
Carine Rivet-Thions Associate Director Regulatory Affairs Labeling @ argenx
Associate Director Regulatory Affairs Labeling
2022-02-01
Hans De Haard CSO @ argenx
CSO
2008-01-01
Peter Verheesen Research Fellow @ argenx
Research Fellow
2016-08-01
Christophe Blanchetot Research Fellow @ argenx
Research Fellow
2011-03-01
Tim Van Hauwermeiren Founder and CEO @ argenx
Founder and CEO
2008-07-01
Karen Massey Chief Operating Officer @ argenx
Chief Operating Officer
2023-03-01
Eric Castaldi CFO @ argenx
CFO
Peter Peter Ulrichts Scientific Lead Neuromuscular Franchise @ argenx
Scientific Lead Neuromuscular Franchise
2019-08-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2022-11-30 | Food and Drug Administration - Priority Review Voucher | Food and Drug Administration - Priority Review Voucher acquired by argenx | 102 M USD |
Investors List
Burrage Capital
Burrage Capital investment in Post-IPO Equity - argenx
MPM Capital
MPM Capital investment in Post-IPO Equity - argenx
Dafna Capital Management
Dafna Capital Management investment in Post-IPO Equity - argenx
Aquila Capital
Aquila Capital investment in Post-IPO Equity - argenx
Erasmus MC Biomedical Fund
Erasmus MC Biomedical Fund investment in Series B - argenx
PMV
PMV investment in Series B - argenx
Omnes Capital
Omnes Capital investment in Series B - argenx
Seventure Partners
Seventure Partners investment in Series B - argenx
OrbiMed
OrbiMed investment in Series B - argenx
Forbion Capital Partners
Forbion Capital Partners investment in Series B - argenx
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-08-22 | OncoVerity | argenx investment in Series A - OncoVerity | 30 M USD |
| 2019-02-06 | Halozyme Therapeutics | argenx investment in Post-IPO Equity - Halozyme Therapeutics | 30 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2023-03-02 | argenx Announces Planned Transition of Chief Operating Officer |
Official Site Inspections
http://www.argenx.com Semrush global rank: 674.59 K Semrush visits lastest month: 46.44 K
- Host name: 151.101.3.10
- IP address: 151.101.3.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "argenx"
About - One Team, One Culture, One Purpose - Argenx
Luc Truyen is the Chief Medical Officer of argenx and joined the company in 2021. Previously, Luc was with the Johnson & Johnson organization for over 20 years holding various leadership …See details»
Company Profile - argenx Annual Report 2023
On May 5, 2017, we transferred the legal ownership of all intellectual property rights of argenx SE to argenx BV, effective retroactively as of January 1, 2017. As a result, since January 1, 2017, (i) argenx BV holds all legal and economic …See details»
Organization and Operations - argenx Annual Report 2023
Through argenx’s collaboration with Zai Lab, we have an interest in business operations in Greater China. Any unfavorable government policies on international trade, including tariffs, …See details»
Our Commitment to Patients - Argenx
Argenx is committed to improving the lives of people suffering from severe autoimmune diseases. We aim to do this in partnership; by listening to patients, supporters and advocacy communities and hearing your stories. It is your …See details»
argenx Canada Inc - Life Sciences Ontario Site - LSO Member …
Argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its …See details»
argenx - Crunchbase Company Profile & Funding
Organization. argenx . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. argenx is a global immunology company committed to improving the lives of people suffering …See details»
Ethics and Responsibility - Argenx
At argenx, we are on a journey together to achieve the unthinkable. We are all working hard to build an integrated immunology company and reach patients. ... and (2) to promote a culture of …See details»
Grants - argenx
However, argenx clinical interests will be prioritized. The approval of a grant application is competitive in nature and the final decision is made by the argenx grant review committee. ...See details»
Reaching Patients Through Immunology Innovation - argenx
At argenx, we’ve created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease …See details»
argenx: Culture - LinkedIn
Argenx | 77,378 followers on LinkedIn. United in our commitment to improve the lives of patients | argenx is a global immunology company committed to improving the lives of people living with ...See details»
Argenx Company Profile - Office Locations, Competitors, Revenue …
Oct 29, 2024 Argenx has 5 employees across 5 locations and $1.23 b in annual revenue in FY 2023. See insights on Argenx including office locations, competitors, revenue, financials, …See details»
Company Profile - argenx Annual Report 2022
Argenx was founded on April 25, 2008 and is registered with the trade register of the Dutch Chamber of Commerce under number 24435214. Our registered office is at Laarderhoogtweg …See details»
argenx Highlights Strategic Priorities for 2022
Year for argenx,” continued Mr. Van Hauwermeiren. Strategic Priorities. The following strategic priorities for support the ‘argenx 2025’ vision2022 to become a global, integrated immunology …See details»
Our Story - Argenx
Get argenx news and updates right to your inbox. Subscribe. Download assets Get photos, fact sheets, illustrations and more. Download now. Join the team Dare to do more with a thriving …See details»
Strategy and Objectives - argenx Annual Report 2022
Implement our “argenx 2025” vision. We hope to make efgartigimod globally available to patients across our four commercial franchises. We aspire to make efgartigimod either commercially …See details»
argenx | argenx Highlights 2024 Strategic Priorities
Jan 7, 2024 argenx SE (Euronext & Nasdaq: ARGX), ... Today, we have built a formidable global commercial organization with product approvals in over 30 countries worldwide and a vibrant …See details»
Argenx: The Magic May Be Already Priced In - Seeking Alpha
1 day ago argenx is a Dutch commercial biotech that was founded in 2008. It was initially a private company but went public in 2014, listing in Europe and NASDAQ IPO in 2017 to …See details»
Innovation - The Science of Collaboration - Argenx
The Immunology Innovation Program (IIP) is a core business strategy of argenx connecting the specialized insight into disease and target biology of our external scientific and academic …See details»
argenx Highlights Strategic Priorities for 2022
Argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its strategic …See details»
Biotechbedrijf Argenx, het op een na waardevolste bedrijf op …
Jan 13, 2025 Het Belgische biotechbedrijf Argenx belooft dat het in 2025 voor het eerst in zeventien jaar winst zal maken. Die belofte leidde prompt tot een recordkoers op de beurs. De …See details»